Concentrations of danofloxacin 18% solution in plasma, milk and tissues after subcutaneous injection in dairy cows

Mestorino, Nora; Marchetti, María Laura; Turic, Esteban; Pesoa, J.; Errecalde, Jorge Oscar

doi:10.1016/j.aca.2008.09.055

Cited by 23 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The transfer of DANO from blood to milk was very rapid with maximum milk concentration having been reached only 8 h after the administration. On the basis of their study, Mestorino et al (2009) recommend the use of 18% DANO administered subcutaneously for the treatment of mastitis and other infectious diseases in dairy cattle provided that a 3-day withdrawal period is observed.…”

Section: Resultsmentioning

confidence: 99%

Fluoroquinolone residues in raw cow's milk

Navrátilová¹,

Borkovcová²,

Vyhnálková³

et al. 2011

Czech J. Food Sci.

View full text Add to dashboard Cite

Navrátilová P., Borkovcová I., Vyhnálková J., Vorlová L. (2011): Fluoroquinolone residues in raw cow's milk. Czech J. Food Sci., 29: 641-646.The aim of the study was to monitore the levels of fluoroquinolone residues in bulk samples of raw cow's milk. The bulk samples of raw cow's milk (n = 150) were obtained from 58 different milk suppliers in the South Moravian and Vysočina Regions. The samples were analysed by reverse phase high-performance liquid chromatography method with fluorescence detection and gradient elution. 87.3% of the raw milk samples were positive for the fluoroquinolones residues. Flumequine was present in none of the samples. The levels of other fluoroquinolones investigated were below the recommended maximum residue limit. The results of the study indicate that fluoroquinolones are frequently administered to the dairy cows in spite of the recommendations of CVMP. The most frequently determined was enrofloxacin and its indicator residue, i.e. ciprofloxacin. An efficient control of the veterinary drugs residues in milk is very important to ensure the safety of the milk and milk products.

show abstract

Section: Resultsmentioning

confidence: 99%

Fluoroquinolone residues in raw cow's milk

Navrátilová¹,

Borkovcová²,

Vyhnálková³

et al. 2011

Czech J. Food Sci.

View full text Add to dashboard Cite

show abstract

“…However, a formulation of danofloxacin 18% was recently developed to allow the delivery of a higher dose (6 mg/kg). As fluoroquinolone antibacterial efficacy is dependent on the peak concentration obtained rather than the duration of plasma concentrations above the minimum inhibitory concentration (Rowan et al, 2004), the efficacy of the 18% formulation has advantages compared with the 2.5% formulation, as the former allows the administration of higher concentrations in a lower volume (Mestorino et al, 2009). Furthermore, this formulation has been reported as safe and effective in the treatment of pneumonia, enteritis, and mastitis with a single dose or at most 2 doses (Poutrel et al, 2008;Mestorino et al, 2009), with the drug reaching high concentrations in different ruminant species (Escudero et al, 2007), thus potentially reducing selection pressure for bacterial resistance (Martinez et al, 2006).…”

Section: Short Communicationmentioning

confidence: 99%

Short communication: The gain-of-function Y581S polymorphism of the ABCG2 transporter increases secretion into milk of danofloxacin at the therapeutic dose for mastitis treatment

Otero

Barrera

Fuente

et al. 2015

Journal of Dairy Science

View full text Add to dashboard Cite

The ATP-binding cassette transporter ABCG2 restricts the exposure of certain drugs and natural compounds in different tissues and organs. Its expression in the mammary gland is induced during lactation and is responsible for the active secretion of many compounds into milk, including antimicrobial agents. This particular function of ABCG2 may affect drug efficacy against mastitis and the potential presence of drug residues in the milk. Previous in vitro and in vivo studies showed increased transport of several compounds, including fluoroquinolones, by the bovine ABCG2 Y581S polymorphism. Our main purpose was to study the potential effect of this bovine ABCG2 polymorphism on the secretion into milk of the antimicrobial danofloxacin administered at the therapeutic dose of 6mg/kg used for mastitis treatment. In addition, the effect of this polymorphism on the relative mRNA and protein levels of ABCG2 by quantitative real-time PCR and Western blot were studied. Danofloxacin 18% (6mg/kg) was administered to 6 Y/Y homozygous and 5 Y/S heterozygous cows. Danofloxacin levels in milk and milk-to-plasma concentration ratios were almost 1.5- and 2-fold higher, respectively, in Y/S cows compared with the Y/Y cows, showing a higher capacity of this variant to transport danofloxacin into milk. Furthermore, the higher activity of this polymorphism is not linked to higher ABCG2 mRNA or protein levels. These results demonstrate the relevant effect of the Y581S polymorphism of the bovine ABCG2 transporter in the secretion into milk of danofloxacin after administration of 6mg/kg, with potentially important consequences for mastitis treatment and for milk residue handling.

show abstract

“…DAF shows a broad spectrum of activity against most Gram-negative, Grampositive bacteria and mycoplasma, but has poor activity against anaerobes (Shojaee Aliabadi & Lees, 2003). FQ share some characteristics such as a broad spectrum of bactericidal activity, a large volume of distribution, low plasma protein binding and relatively low minimal inhibitory concentrations (MICs) against target microorganisms (Otero et al, 2001a;2001b;Mestorino et al, 2009). Danofloxacin 18% was demonstrated to be effective in the treatment of bacterial pneumonia caused by P. multocida, M. hemolytica and H. somnus or bacterial enteritis given as a single injection at a dose rate of 6 mg.kg -1 of body weight, or two doses 48 hours apart, as needed.…”

Section: Danofloxacinmentioning

confidence: 99%